Study:
Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu`s Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis
Rationale:
n/a
Purpose:
Giant cell arteritis (GCA) and Takayasu`s arteritis (TAK) are diseases that cause swelling
of the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta,
the largest blood vessel in the body, and its branches. Therapies are available to improve
the symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed.
Abatacept is a drug that interacts with certain cells in the body that are involved with GCA
and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and
preventing disease relapse.
Study Status: Recruiting
Recruiting:
Carol A. Langford, MD MHS 216-445-6056
| Condition |
Intervention |
Phase |
Takayasu`s Arteritis
Giant Cell Arteritis |
Drug: Abatacept
Drug: Placebo |
Phase 2 |
Verified by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
August, 2012
Sponsored by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
ClinicalTrials.gov identifier: NCT00556439
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
Carol A. Langford, MD, MHS., Principal Investigator